Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer that remains poorly understood at the molecular level. Comprehensive tumor profiling was performed to understand clinically actionable alterations in IBC. Targeted-next-generation sequencing and IHC were performed to identify activated pathways in IBC tumor tissues.
IBC is characterized by rapid onset of breast erythema, edema, enlargement, and the characteristic peau d'orange appearance of the skin. The inflammatory skin response results from dermal lymphatic invasion, a hallmark of IBC, whereby lymphovascular spaces are occupied by tumor emboli (2) . The presence of multiple dermal and stromal tumor emboli are distinguishing pathologic characteristics of IBC (2) .
Inflammatory signaling pathways are active in IBC (NF-B, Cox-2, and JAK2/STAT3)(1, 5), but the exact function of the immune response remains elusive. Immune cells and inflammatory signaling may promote IBC tumor cell proliferation, angiogenesis, and metastasis(1). On the other hand, the presence of cytotoxic tumor-associated lymphocytes has also been associated with a more favorable breast cancer prognosis (6) . The contradictory nature of the immune data highlights the necessity of elucidating the relationship between the immune response, IBC tumorigenesis, and subsequent treatments. IBC immunotherapies are currently under investigation in the preclinical setting (2) . Given the active IBC immune component and the recent clinical benefit of immune checkpoint inhibitors in cancer treatment (7) , IBCs may represent a clinically unique breast cancer population that may benefit from immunomodulating agents.
Primary IBC treatment involves systemic chemotherapy (taxanes and anthracyclines) followed by surgery and radiation (8) . ERBB2 (hereinafter referred to as "HER2")-positive IBCs may also benefit from trastuzumab, lapatinib, or both (9) . Despite advances in the multimodal IBC treatment regimens, IBC remains a therapeutic challenge. Due to the rareness of the disease, IBC remains poorly understood at the molecular level. Previous molecular profiling studies indicate that IBC is a molecularly distinct subtype of breast cancer, providing preliminary insight into clinically relevant pathways that influence IBC tumorigenesis (10) . For example, HER2 is commonly amplified or overexpressed in IBC (11) , whereas genes typically overexpessed in non-IBC: TGF-, progesterone receptor, and the estrogen receptor (ER) are typically downregulated in IBC (12) . While previous biomarker studies offer insight into IBC, IBC analyses are typically limited to a subset of target molecules or pathways. Genomic IBC data is sparse and new genomic-based analysis offers the potential to identify a robust set of clinically relevant biomarkers (13) . relationship between genotype, tumorigenesis, and the immune response, targeted next-generation sequencing was performed on a panel of cancer-related genes in IBC tumors. The current data provide insight into genomic signatures that drive IBC tumorigenesis and the cell-mediated (T-lymphocyte) immune response. Active IBC pathways range from aberrant HER2/HER3(ERBB3)/PI3K signaling to PD-L1 immune checkpoint signaling, all of which may be amenable to targeted therapeutic intervention (hereinafter ERBB3 is referred to as "HER3").
This study identifies the importance of using a combination of targeted sequencing, immunological analysis, and protein analysis to comprehensively profile human tumors to generate clinically relevant data that provides insight into avenues for therapeutic intervention. Utilizing these approaches we have revealed possible treatment options that may be tailored to the genomic and proteomic background of each cancer. Our study has identified genomic alterations that mechanistically contribute to oncogenic signaling in this aggressive form of breast cancer, and provides a genetic basis for the selection of clinically relevant targeted and combination therapeutic strategies. Furthermore, an NGS-based estimate of neo-antigen exposure developed in this study may be a useful biomarker to predict immune cell infiltration in IBC and other cancers, and this biomarker may be associated with greater levels of response to immunotherapies such as PD-L1/PD-1 targeted therapies.
MATERIALS AND METHODS

Next-Generation Sequencing of IBC Tumor Samples
Sample preparation, library construction and targeted capture, next-generation sequencing, and bioinformatics analyses of tumor and normal samples were performed by Personal Genome Diagnostics (PGDx, Baltimore, MD). A custom hybridization capture based probe library was designed using Agilent SureSelect capture probes (Agilent Technologies; Supplementary Table S1 ). This panel captures full coding regions of 208 cancer relevant genes and introns of 13 genes to detect the substitution, deletions, copy number changes in the 208 targeted genes and structural rearrangements in 17 genes. Indexed Illumina NGS libraries were prepared from tumor enriched samples specified in performed on formalin-fixed, paraffin-embedded (FFPE) tissues. Tumor tissues, including the cancer stage at diagnosis (and all available clinical information), are described in Supplementary Table S2. A pathologist scored/estimated the   percentage of cancer tissue in each tissue sample (Supplementary Table S2 )
Bioinformatic analyses
Sequencing reads were analyzed and aligned to human genome hg18 with the Eland algorithm in CASAVA 1.7 software (Illumina). Reads were mapped using the default seed-and-extend algorithm, which allowed a maximum of two mismatched bases in the first 32 bp of sequence. Identification of somatic alterations was using the VariantDx (PGDx, Baltimore, MD) next-generation sequencing analysis pipeline that enriched for tumor-specific single-nucleotide alterations and small indels. Briefly, for each position with a mismatch (compared with the hg18 reference sequence using the Eland algorithm), the read coverage of the mismatched and wildtype sequence at that base was calculated. For determination of tumor-specific alterations, tumor were compared and known polymorphisms were removed from the analysis. Potential somatic mutations were filtered and visually inspected, and a candidate-mismatched base was identified as a mutation when distinct paired tags contained the mismatched base and the mismatched base was not present in the matched normal sample.
Cell Culture
AU565 Cells [AU-565] (ATCC®CRL-2351™) and BT474 Cells (ATCC®HTB-20™) were purchased from American Type Culture Collection (ATCC; 2011) and expanded upon receipt into vials of low-passage cells for cryopreservation. Cells were passaged for up to 3 months after resuscitation. ATCC characterizes cell through short tandem repeat typing, and re-authentication was not conducted. AU565 cells were cultured in RPMI-1640 and BT474 cells were cultured in Iscove's Modified Dulbecco Minimum Essential Medium. All media were purchased from Corning and supplemented with 10% FBS (Life Technologies) and antibiotics (Corning). Cells were cultured in a 37°C, 5%CO2 humidified environment.
siRNA Knockdown 
Western Blot Analysis
Following 72 h treatment with Scrambled Control or ERBB3 siRNA, cell lysates were collected in protein lysis buffer (Cell Signaling) supplemented with PMSF (Sigma-Aldrich), PI cocktail (Sigma-Aldrich), and PhosphoGuard A/B (Therapak). Protein concentrations were determined using the Lowry assay (Bio-Rad) and 30 g of protein was resolved on 4-15% gels (Bio-Rad). After transfer to PVDF membranes, blots were incubated in LI-COR blocking buffer (LI-COR Biosciences) and probed with primary antibody overnight at 4 C. pERBB3, pS6 (Ser235/236), total S6 and GAPDH antibodies were from Cell Signaling; -actin antibody was from Sigma-Aldrich and total ERBB3 antibody was from EMD Millipore . Appropriate secondary antibody (LI-COR Biosciences) was utilized to visualize bands on a LI-COR Odyssey® Infrared Imaging System (LI-COR Biosciences). Western blot experiments were repeated in triplicate.
Immunohistochemistry
Formalin-fixed paraffin-embedded 5μm sections were stained for phospho-ErbB3, phospho-S6, CD8, were stained with a primary antibody to phospho-ErbB3 at a 1:500 for 30 minutes, phospho-S6 at a 1:100 for 30 minutes, CD8 (predilute) for 20 minutes, PD-L1 at 1:100 for 30 minutes and FoxP3 at 1:100 for 60 minutes. All other reagents used in the staining process were Dako Evision Flex Reagents (Dako). Hematoxylin (Surgipath/Leica) was used as the counterstain. Image analysis was performed on an Aperio Scanscope XT using Spectrum Software. immune cell infiltration was present in the superficial dermis layer and was associated with intra-tumoral and contiguous peri-tumoral desmoplastic stroma (Fig. 1A) . High-throughput targeted-next-generation sequencing was used to characterize genetic variants in a panel of 208 cancer-related genes across IBC tissues. The NGS (next-generation sequencing) generated approximately 0.8 Mb of target region sequence and >94% of the target regions were defined by at least 10 reads. Analysis of the types of genetic variants reveal that missense mutations were the most common variant (73%), followed by frameshifts (8%), splice site alterations (6%), nonsense mutations (5.5%), amplifications altered genes in IBC, it is noteworthy that genetic alteration of APC, ATM, and HER3 occur at low frequencies in noninflammatory breast cancer (0.5%, 2.1%, and 1-4%, respectively) (16, 17) . Whereas TP53, and HER2 variants occur at elevated frequencies in both IBC and non-inflammatory breast cancer(33% and 30%, respectively)(18).
RESULTS
Targeted
In total, 47 genes have alterations in at least three independent IBC tumor samples. The allelic frequency differs between tumor samples, and several allelic variants are present at a high frequency in multiple tumors (Fig. 1C) . High frequency intratumoral allelic variants (ex. TP53, EGFR, PMS2) may represent trunk mutations present in the bulk of the tumor that occur early in IBC tumorigenesis ( Fig. 1C) (19) .
Pathway analysis of the NGS data reveals prominent genomic variation of core biologic pathways in multiple IBC tumors ( Fig. 1D) . Genes with reoccurring variants across IBC tumors grouped into distinct biologic pathways, and the most frequent gene alterations occur in pathways that influence genomic stability/DNA repair, PI3K signaling, chromatin modification, and HER signaling.
Frequent Genomic Alterations in the PI3K/mTOR Pathway in IBC
Pathway analysis revealed that IBC tumors are characterized by frequent genomic alterations in the HER/PI3K/mTOR pathway (Fig. 1B) . PI3K can promote oncogenic signaling through the activation of the mTOR (mammalian target of rapamycin) pathway. Phosphorylated ribosomal protein-S6 (pS6) is a surrogate marker for mTOR activation and subsequent mTOR-mediated proliferation signals. In order to investigate activity of this pathway in IBC samples, IBC tissues were immunohistochemistry stained for pS6 expression. Ninety-five percent (n=18) of IBC tumors stained strongly positive for pS6, which suggests that the PI3K/mTOR pathway is active in the majority of IBC tumors.
Mechanistically, specific genomic alterations may activate the HER/PI3K/mTOR pathway through an increase in oncogene signaling or a decrease in tumor suppressor activity thus contributing to IBC tumorigenesis ( Fig. 2A) .
Twenty-one percent of IBC tumors contained mutations in PIK3CA (Fig. 1B) , and all of the reported PIK3CA mutations occur in previously characterized regions of mutational hotspots (20) . In addition to the genetic variants that may potentiate oncogenic signaling in the PI3K/mTOR pathway, the IBC tumors also harbored mutations that may disrupt the activity of tumor suppressor genes in the PI3K/mTOR pathway. NGS analysis revealed mutations that may lead to a loss of function in the tumor suppressors TSC1, TSC2 and PTEN, all of which are important negative regulators of the PI3K/mTOR pathway. Forty percent of IBC tumors harbor a mutation or a deletion in TSC1 or TSC2 (Fig. 1B) . NGS analysis of PTEN revealed one deletion event in the IBC tumor cohort (Supplementary Table S3A-S3C) . Taken together, the gain-of-function alterations in oncogenes, and loss-of-function mutations in tumor suppressors may contribute to the high activity level of the PI3K/mTOR pathway in IBC tumors ( Fig. 2A) .
Frequent HER3 Hotspot Mutations in IBC
In agreement with previous studies, HER2 was amplified in 53% of IBC tumors (21) . Moreover, HER3 was mutated in 26% (n=5) of IBC tumors, which is higher than HER3 mutational rates reported for gastric cancer (12%), colon cancer (11%), and non-inflammatory breast cancer (1-4%) (17, 22) . Interestingly, 4 of the 5 HER3 alterations occur in regions of mutational hotspots that are located in the extracellular domain or the kinase domain of HER3 (Fig. 2B) . It is also noteworthy that 4 of the 5 HER3 mutations co-occur with HER2 amplification (Fig. 1B) (17) .
The high activity of the HER/PI3K pathway across IBC tumors and the relatively high HER3 mutation rates in IBC tumors indicate that HER3 may play a functional role in IBC. To determine if HER3 mutants influence downstream signaling, we examined IBC tumors for the presence of activated (phosphorylated) HER3 (Fig. 2C, 2D ).
Immunohistochemistry (IHC) analysis reveals elevated levels of phosphorylated HER3 in IBC tumor samples with HER3 mutations (Fig. 2D) . A subset of IBC tumors, with high levels of phosphorylated-HER3, simultaneously possess an amplified HER2 and a mutant HER3 (Fig. 2D ).
To further elucidate the role of HER3, we carried out functional assays in breast cancer cell lines. The lack of specific HER3 mutant/HER2 Amplified IBC cells lines prompted the use of AU565 and BT474 which possess the desired HER2/HER3 status (AU565 [HER3 mutant (kinase domain); HER2 amplification] and BT474 [HER3 wild-type; HER2 amplification]). In cell lines AU565 and BT474, transfection of HER3-targeted siRNA led to a decrease in both the phosphorylated and unphosphorylated forms of HER3. The HER3-targetd siRNA also produced a significant drop in proliferation in AU565 cells but not BT474 cells (Fig. 2E) , which suggests that mutant HER3 signaling may contribute to the proliferative phenotype of breast cancer cells. The scrambled siRNA control did not alter the proliferation or the levels of phosphorylated HER3 in either cell line (Fig. 2E) . Western blot analysis of phosphorylated ribosomal protein S6 (S6), a surrogate marker of mTOR activity, revealed that phosphorylated S6 levels decrease in response to HER3- targeted siRNA in AU565 cells but not in BT474 cells (Fig. 2E) . In both AU565 and BT474, the levels of unphosphorylated S6 did not change following transfection of the HER3-targeted siRNA (Fig. 2E) , which suggests that elevated levels of phosphorylated S6 may be due to an increase in upstream HER signaling pathways.
Subset of IBC tumors are characterized by extensive immune infiltration
Recent studies suggest the importance of immune cells in the progression and treatment of cancer, and we sought to define the nature of the immune response in the current IBC cohort. Pathological examination of IBC tissues identified a subset of IBC tumors associated with infiltration of immune or inflammatory cells. To further investigate the nature of these infiltrates, CD8 (cytotoxic T cell marker) and FOXP3 (T regulatory cell marker) IHC staining was performed on tissues to characterize T cells populations present in each tumor. Twelve IBC tumors had sufficient tissue for IHC analysis. Infiltrates stained minimally for FoxP3+ Tregs (Fig. 3A) . IHC staining identified the majority of infiltrating cell populations as CD8+ cytotoxic T cells (Fig. 3B) . CD8+ T cells typically localized in associated intra-tumoral and contiguous peri-tumoral desmoplastic stroma. Negative regulation of CD8+ T cells may explain the high level of CD8+ TILs at the periphery of IBC tumors (Fig. 3D) .
Recent studies highlight the importance of PD-L1 (Programmed cell Death receptor-Ligand 1) mediated immune resistance in tumor progression. This immune checkpoint signaling molecule inhibits T-cell activation and its expression has been previously reported in both tumor and infiltrating immune cells. In order to explore the possible role of PD-L1 in IBC, we IHC stained IBC tissues for PD-L1 (Fig. 3D, 3E) . Evaluation of PD-L1 staining demonstrated low-intensity tumor cell staining in 3/12 tumors studied and high-intensity tumor cell staining in 1/12 tumors (Fig. 3F) (Fig. 3F) . Intensity of PD-L1 staining on immune infiltrates was generally high with IHC scores typically ranging from 2+ to 3+ (Fig. 3D) .
Mutation rates correlate with extent of immune cell infiltration in IBC
In order to further understand the differences in levels of immune cell infiltration between IBC tumors, NGS data was analyzed in tumors with high and low levels of immune infiltrate (Due to limited tissue availability 12 of 19 IBC samples were available for IHC analysis). Notably, somatic mutation rates were significantly higher in high infiltration vs low infiltration tumors (Fig. 4A, p<0.05) . We rationalized that this correlation between somatic mutation rate and immune cell infiltration may be related to the exposure of tumor neo-antigens to the immune system. We next proposed that a score (iScore) that combines the somatic mutation rate and average mutant allele frequency may better represent the level and variability of neo-antigens throughout the bulk of the tumor. The iScore is calculated by multiplying the average mutant allele frequency by the total number of somatic mutations in the tumor. Comparison of iScores between high infiltration and low infiltration tumors demonstrated high significance in the association between levels of CD8+ infiltration and iScore in IBC tumors (Fig. 4B, p<0.01) , suggesting that the iScore may be a reliable NGSbased estimate of immune infiltrate in IBC tumors. It is noteworthy that, when compared to the somatic mutation rate alone (Fig. 4A) , the iScore more significantly distinguishes tumors with either high or low levels of CD8+ cell infiltration (Fig. 4B) .
NGS data reveals that more than 90% of IBC tumors harbor mutations in genes that contribute to "Genome Stability & DNA repair" (Fig. 1D) . We proposed that alterations in DNA repair pathways may explain the variations in somatic mutation rates among IBC tumors (ranging from 6-78 mutations/megabase; Supplementary Table S3C) .
Interestingly, 43% of IBC tumors possess alterations in at least one gene in the DNA mismatch repair (MMR) pathway (Fig. 5) . Tumors with higher somatic mutation rates typically were associated with more frequent alterations in MMR genes and often harbored multiple mutations in the MMR pathway (Fig. 5) . NGS revealed mutations in the following MMR pathway members: PMS2 (nonsynonymous mutations), MSH2 (nonsynonymous mutations), MSH6 (nonsense mutation and frameshift), and MLH1 (nonsense mutation). It is noteworthy that specific IBC mutations in MSH2 and PMS2 have also been reported in an inherited disorder, Lynch syndrome, which is linked to higher rates of colon cancer(23) and characterized by mutations in the DNA MMR pathway (24) .
In addition, alterations in epigenetic signaling pathways may contribute to MMR in IBC. The chromatin remodeling genes ARID1A and ARID1B also have a role in DNA MMR (25) . Genetic alterations in either ARID1A or ARID1B are found in 6 of 19 IBC tumors (Fig. 5) , indicating that aberrant epigenetic signaling may disrupt DNA repair and ultimately contribute to IBC progression. It is noteworthy that ARID1A variants occur in 26% of the current IBC cohort, whereas only 2% of non-IBC tumors harbor mutations in
ARID1A(16).
In IBC samples, nonsense mutations and frameshifts in MMR genes are likely to disrupt the function of a wildtype protein, however, nonsynonymous mutations may also disrupt protein function. For example, the nonsynonymous PMS2 mutation (D575G) which occurred in one IBC sample is located within a protein domain ("level" domain) which interacts with MSH6 and is important to PMS2 function (26) . The functional characterization of IBC variants in MMR genes warrants further study. Albeit a limited size IBC tumor cohort, high immune cell infiltration positively correlates with the presence of MMR gene alterations in comparison to IBCs with low immune cell infiltration (Fig. 3C ).
DISCUSSION
In this study, we performed targeted NGS to profile a panel of 208 cancer-associated genes in 19 IBC tumors.
Although the current study is based on a small cohort, the targeted exome analysis provides compelling evidence that specific biologic pathways and somatic variants may influence IBC tumorigenesis and the concomitant immune response. The genomic profiling may also provide a clinically relevant means to stratify patients into cohorts that may benefit from targeted therapeutics.
NGS data reveals somatic alterations in pathways that regulate HER/PI3K signaling, chromatin modification, and DNA repair in IBC. The biologic significance of these pathways is supported by independent studies demonstrating that PI3K, HER2, and DNA repair genes are altered in IBC tumors (27) . In our cohort, the most abundant somatic alterations occur in genes that contribute to HER/PI3K/mTOR signaling, and IHC indicates that downstream effector pathways are active in a majority of IBC tumors. cancer (29) . Notably, HER3 is altered in 26% of IBC tumors, which is higher than the HER3 mutation rates reported in other tumors (1-12%) (17, 22) . Variants typically occurred in known mutational hotspot regions in the kinase and extracellular domains of HER3 and frequently co-occurred with HER2 amplification. In our study, tumors harboring HER3 mutations were associated with higher levels of tumoral expression of phosphorylated HER3, which provides further evidence that HER3 mutation may be associated with constitutive HER3 activation in IBC. Other studies have demonstrated that somatic HER3 mutations may promote ligand-independent oncogenic signaling and increased sensitivity to HER3 targeted therapies (17) . Cell line studies also suggest a role for mutant HER3 in IBC. siRNA-mediated activity and frequent alterations in the pathway, IBCs may benefit from targeted disruption of PI3K/mTOR activity. The potential benefit of an mTOR-targeted therapy was demonstrated by the BOLERO-3 trial, in which the mTOR inhibitor, everolimus, was shown to provide a clinical benefit in the treatment of trastuzumab-resistant, HER2-positive breast cancer (35) . While PIK3CA activating-mutations are associated with better response to PI3K targeted therapies, they are also associated with a poor response to HER2-targeted therapies in breast cancer (36) , raising the possibility that PIK3CA status should be taken into account with respect to the effectiveness of HER-targeted therapies in IBC. Conversely, the HER2/HER3 status may impact the efficacy of PI3K inhibitors. For example, the PI3K-inihibitor, XL147, inhibits cell growth in wild-type HER2 breast cancer cells, but not in HER2-amplified breast cancer cells(37). HER-2 amplified breast cancer cells became susceptible to XL147 following the knockdown of HER3 or adjuvant treatment with trastuzumab or lapatinib(37). Collectively, the interplay of genetically altered cancer pathways raises important considerations for treatment of IBC and other cancers.
The majority of IBC tumors harbor mutations in genes that contribute to genome stability and DNA repair.
Genetic alterations in DNA repair pathways may disrupt the fidelity of DNA repair and thus contribute to the development and progression of IBC. Notably, in our study, we have detected frequent alterations in the MMR pathway in IBC tumors that correlate with higher somatic mutation rates and greater levels of immune infiltration. The occurrence of MMR gene variants in IBC has not been previously reported and thus the role that these genetic alterations play in IBC progression is less clear. In Lynch syndrome, a hereditary syndrome associated with high rates of colorectal cancer development, somatic variants in DNA MMR genes (PMS2, MSH2, MSH6, and MLH1) leads to microsatellite instability (MSI) (24) . Prior studies have also identified that MSI is associated with elevated TIL levels that may be related to the neoantigens that arise from errors in MMR (38) . Furthermore, high somatic mutation rates have also been linked to higher tumor antigenicity in other cancers through the production of immune-response-eliciting neoantigens (39) . Somatic mutations play a significant role in neoantigen production that triggers a T-cell response (40) .
Alterations in the MMR pathway are typically associated with the generation of frequent somatic point and frameshift mutations that may disrupt protein function and create immunogenic neoantigens (39) . It is tempting to speculate that alterations in the MMR pathway in IBC may have similar links to somatic mutation rate and levels of immune infiltration, however, further mechanistic studies are required to support this hypothesis. 
To further characterize immunogenicity in IBC, we developed an NGS-based estimate of antigen exposure, the iScore. The iScore takes into account both the somatic mutation rate and average mutant allele frequency for each individual tumor. The iScore more significantly characterized TIL levels than somatic mutation rates alone, which suggests that mutant allele frequency may be an important factor for the estimation of tumor antigenicity and TIL levels.
Since somatic mutations contribute to neoantigen production and a TIL response, the average mutant allele frequency of the somatic mutations may serve as a quantitative measure of neoantigen exposure and the subsequent TIL response (39) . Furthermore, incorporation of mutant allele frequency accounts for the prevalence of DNA variants throughout the bulk of the tumor. The importance of TILs in breast cancer is highlighted by an analysis of breast cancer stroma that reveals a correlation between a favorable prognosis and the expression of CD8+ T cell-related genes (41) . In addition, a cohort analysis of breast cancer patients revealed a positive correlation between CD8+ T cell density and improved clinical outcome (42, 43) . While the iScore is significantly associated with TIL infiltration in IBC tumors, there are also many other factors that may play a role in controlling this process and as such further multivariate analysis is required in a larger cohort to better characterize this relationship.
TILs may disrupt tumor progression in IBC, but an optimal anti-tumor response requires the presence of functional T-cells. TILs are often in a state of T-cell exhaustion, a T-cell phenotype that is defined by poor effector function (44) . T-cell exhaustion is typically associated with the expression of immune checkpoint inhibitors, such as PD-L1 on tumor cells and/or TILs (45, 46) . Within the context of the breast cancer microenvironment, upregulation of PD-L1 may contribute to immune evasion (47) . High levels of PD-L1, detected in tumors in this study, may negatively regulate T cells thus preventing the activation and migration of CD8+ T cells into the tumor. The presence of CD8+ T-cells is a strong predictor of response to anti-PD-L1 therapy (48) , and PD-L1 expression is also predictive of a clinical response to anti-PD-L1 therapies (46, 49) . It is noteworthy that a response to PD-L1 therapy is strongly associated with immune cell PD-L1 expression, which is characteristic of IBC rather than tumor cell PD-L1 expression (49) . 
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